After promising efficacy of anti-PD-1/PD-L1 mAbs in smaller single-arm trials, randomized phase III trials first in the platinum failure setting and then in the frontline setting were conducted and have changed the standard of care systemic treatment for R/M HNSCC patients. The gene discussed is PDCD1; the disease is head and neck squamous cell carcinoma.